CheckMate 9LA is a phase III trial in which naive patients with advanced NSCLC and no molecular drivers were randomized to receive the combination nivolumab plus ipilimumab plus two cycles of standard platinum-based chemotherapy, or standard platinum-based chemotherapy alone, regardless of PD-L1 expression and histology. This evidence concerns the gene CD274 and non-small cell lung carcinoma.